1621619-37-1

Basic information

• Product Name: 4-[(6-methyl-2,2-dioxido-4-oxo-1,2,3-oxathiazin-3(4H)-yl)methyl]benzonitrile
• Synonyms: 4-[(6-methyl-2,2-dioxido-4-oxo-1,2,3-oxathiazin-3(4H)-yl)methyl]benzonitrile
• CAS NO: 1621619-37-1
• Molecular Weight: 278.288
• Mol File: 1621619-37-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[(6-methyl-2,2-dioxido-4-oxo-1,2,3-oxathiazin-3(4H)-yl)methyl]benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(6-methyl-2,2-dioxido-4-oxo-1,2,3-oxathiazin-3(4H)-yl)methyl]benzonitrile(1621619-37-1)
• EPA Substance Registry System: 4-[(6-methyl-2,2-dioxido-4-oxo-1,2,3-oxathiazin-3(4H)-yl)methyl]benzonitrile(1621619-37-1)

Safety Data

• Hazardous Substances Data: 1621619-37-1(Hazardous Substances Data)

Upstream product

• 55589-62-3 potassium acesulfame 
• 17201-43-3 4-cyanobenzyl bromide 

Relevant articles and documents

Cyclic tertiary sulfamates: Selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives

Carbonic anhydrase (hCA) IX and XII isoforms are over-expressed both in primary and in metastatic cell lines of hypoxic tumors and are innovative targets for cancer diagnosis and treatment. On the basis of the importance of the pharmacophoric sulfamate moiety (bioisostere of the sulfonamide group) present in the structure of recent human CA inhibitors, we designed N-alkylated and O-alkylated derivatives of acesulfame, a cyclic tertiary sulfamate, assessing the inhibitory activity against the ubiquitous isoforms hCA I and II and the cancer-related isoforms hCA IX and XII. All derivatives were nanomolar inhibitors, with some of them possessing an outstanding selectivity towards the tumor-associated hCA IX and/or hCA XII isoforms.